A multitude of humanized monoclonal antibodies for asthma treatment are currently undergoing clinical development, which include tezepelumab (targeting TSLP) as well as etokimab, itepekimab, astegolimab (AMG 282), torzorakimab, and melrilimab (GSK3772847) for IL-33 (Table 1). Here, TSLP is linked to asthma.